The narcolepsy treatment market is projected to grow from USD 5,301.6 million in 2024 to USD 8,718.3 million by 2034, at a ...

Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...

Hallucinations. Sleep paralysis. Excessive daytime sleepiness. Jenny Lee-Gilmore was diagnosed with Type 1 narcolepsy at 21 — seven years after she first went to a doctor about her symptoms. This is ...

Avadel Pharmaceuticals missed the fourth quarter sales estimate by 5.12%. Still, the sales of its narcolepsy drug, LUMRYZ ...

Copay Assistance From The Assistance Fund Now Available for Eligible People Living With Narcolepsy. ORLANDO, FLORIDA / ACCESSWIRE / January 9, 2025 / The Assistance Fund, an indep ...

The FDA has expanded the approval of Lumryz (sodium oxybate) extended-release oral suspension to include treatment of pediatric narcolepsy.

Central nervous system (CNS) specialist Neuraxpharm Group has acquired Provigil (modafinil) and Nuvigil (armodafinil), both ...

The idea that autism is caused by vaccines has recently been revived by Robert F. Kennedy Jr., the presumptive nominee for US ...

Speaking at the JP Morgan Healthcare Conference 2025 yesterday (14 January), Cozadd said: “We’ve got some really exciting ...

Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces today that it has acquired at the end ...

Avadel Pharmaceuticals expects its narcolepsy treatment Lumryz to drive strong revenue growth in the fourth quarter and into 2025, preliminary earnings show.